Clinical Trials Directory

Trials / Active Not Recruiting

Active Not RecruitingNCT07362030

Drug-durg Interaction of RAY1225 With Warfarin, Atorvastatin, Metformin and Digoxin

A Open-Label, Phase I Drug-drug Interaction Clinical Study to Investigate the Pharmacokinetics of RAY1225 With Warfarin, Atorvastatin, Metformin and Digoxin in Healthy Participants

Status
Active Not Recruiting
Phase
Phase 1
Study type
Interventional
Enrollment
32 (actual)
Sponsor
Guangdong Raynovent Biotech Co., Ltd · Industry
Sex
All
Age
18 Years – 55 Years
Healthy volunteers
Accepted

Summary

The drug-drug interaction study had been designed to investigate the effect of RAY1225 on the pharmacokinetics of digoxin, Rosuvastatin and

Conditions

Interventions

TypeNameDescription
DRUGRAY1225subcutaneous injection
DRUGatorvastatin calcium tabletOral
DRUGMetformin TabletsOral
DRUGWarfarin Sodium TabletsOral
DRUGDigoxin TabletsOral

Timeline

Start date
2025-04-14
Primary completion
2025-12-27
Completion
2026-03-30
First posted
2026-01-23
Last updated
2026-01-23

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT07362030. Inclusion in this directory is not an endorsement.

Drug-durg Interaction of RAY1225 With Warfarin, Atorvastatin, Metformin and Digoxin (NCT07362030) · Clinical Trials Directory